The digital dose inhaler market size is USD 20.6 Bn in 2026.
The digital dose inhaler market is projected to grow at a CAGR of 6% by 2033.
The market growth drivers include the rise in chronic respiratory diseases, technological advancements in inhalers, and increasing geriatric population.
North America is a dominating region for the digital dose inhaler market.
Propeller Health (ResMed), Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc (GSK), AstraZeneca plc, and Novartis AG are some leading industry players in the digital dose inhaler market.